Skip to main content
OpenTrials
Completed

NCT Number: NCT00597558

Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)

The purpose of this study is to determine if children with egg allergy can be desensitized to egg protein and if this desensitization can help them outgrow their egg allergy at an earlier time than normal. Our hypothesis is that children with egg allergy can be orally desensitized to egg protein and that this desensitization will help them outgrow their egg allergy at an earlier time than normal.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Arkansas, Little Rock, Arkansas, United States

Loading trial locations.

About this study

Egg allergy in children under 5 years of age is extremely common. Egg, along with milk and peanuts, cause 80% of the food allergy reactions in children in the United States. Children have allergic reactions to egg ranging from mild urticaria to systemic anaphylaxis. The current therapy for children with egg allergy is to place the child on an egg-free diet until the allergy is outgrown. Because egg protein is a part of a significant number of processed foods it is difficult to totally avoid all egg proteins. Accidental ingestions leading to reactions to egg can occur with a bite of a cookie (~70 mg of egg protein) or a bite of a cake (~55 mg of egg protein). Children typically do not outgrow their egg allergy for several years. Therefore it would be helpful if a specific form of therapy would make children outgrow their allergic reactions to egg sooner. Egg protein is given to children in this study in small increasing amounts to desensitize them to the egg protein with the goal of helping them to outgrow their allergy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Between 1 to 16 years of age
  • Diagnosed egg allergy by CAP FEIA to egg of 5 kU/l or greater (2 kU/l or greater if 2 years old or less) or have had a positive allergic reaction to egg within 6 months.
  • Having eaten egg in his/her diet prior to diagnosis
  • A family that will be able to be compliant with all study visits
  • All females of child bearing age must be using appropriate birth control

Exclusion criteria

  • History of anaphylaxis to egg
  • Medical history that would prevent a DBPCFC (double-blind placebo-controlled food challenge) to egg. The medical history that would prevent the DBPCFC to egg would be a prior history of an open egg challenge in which the patient experienced hypotension which required fluid resuscitation, respiratory compromise which necessitated ventilatory support, or poorly controlled asthma as evidenced by an FEV1 < 80% of predicted, or FEV1/FVC <75%, with or without controller medications
  • Unable to cooperate with challenge procedures or unable to be reached by telephone for follow-up
  • Diagnosed corn allergy

Treatment and study plan

Egg white protein

Drug

Egg white protein powder

Other names: Egg OIT

Primary outcomes

  1. Double-blind, Placebo-controlled Food Challenge (DBPCFC) to Egg

    Time frame: 24-60 months

    Subjects will have a double-blind, placebo-controlled food challenge (DBPCFC) to egg after at least 24 months of egg OIT when the IgE to egg is < 7 kU/L or 90% of entry level IgE or SPT <= 5mm with a maximum treatment period of 60 months.

Secondary outcomes

  1. Egg Protein Skin Prick Test After Egg OIT

    Time frame: 24-60 months

    Wheal size on egg protein skin prick test at the end of egg OIT treatment compared with at baseline.

  2. Serum CAP-FEIA to Egg

    Time frame: 24-60 months

    Measure of serum CAP-FEIA to egg from subjects on egg OIT after completion of treatment compared to baseline

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Collaborators

  • University of Arkansas

Registry information

Acronym: EggOIT

Important dates

Study start
2003
Primary completion
2014
Study completion
2014
First posted
Jan 18, 2008
Registry last updated
Mar 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.